WHC is still in active development. Read this to understand our approach.
depiction of BRUQQQPBMZOVGD-UHFFFAOYSA-N.svg
tripsit

oxycodone

Check on tripsit

psychonaut

Oxycodone

Check on psychonaut

isomerdesign

Oxycodone

Check on isomerdesign

isomerdesign

14-Hydroxy-3-methoxy...

Check on isomerdesign

pubchem

Oxycodone

Check on pubchem

druglab

Oxycodone

Check on druglab

drugmap

Oxycodone

Check on drugmap

drugmap

Oxycodone

Check on drugmap

wiki

Oxycodone

Check on wiki

Data

InChI: InChI=1S/C18H21NO4/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10/h3-4,13,16,21H,5-9H2,1-2H3

Synonyms: Morphinan-6-one, 4,5alpha-epoxy-14-hydroxy-3-methoxy-17-methyl-,Oxycodonum [INN-Latin],Oxicodona,OxyIR,DB00497,Ossicodone,Dihydrone,percocet,Oxicodona [INN-Spanish],OXYCODONE [USAN],Endone,IDS-NO-002,Oxycodone 1.0 mg/ml in Methanol,(-)-14-Hydroxydihydrocodeinone,oxymorphone 3-methyl ether,Eucodalum,14-Hydroxy-3-methoxy-17-(2H3)methyl-4,5α-epoxymorphinan-6-one,Oxicon,PF-00345439,Supendol [Canada],OOX,Dihydroxycodeinone,Roxicodone,Oxycodone Concentrate,Percobarb,NSC19043,EINECS 200-960-2,OXYCODONE [WHO-DD],Codeinone,8-dihydro-14-hydroxy-,(4R,4aS,7aR,12bS)-4a-hydroxy-9-methoxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one,SCHEMBL2737,C08018,(-)-Oxycodone,Endine (Australia),(5alpha)-14-hydroxy-17-methyl-3-(methyloxy)-4,5-epoxymorphinan-6-one,PTI-821,NSC-19043,DTXSID5023407,Pti 821,oxycodone,Dihydro-14-hydroxycodeinone,CHEBI:7852,OXYCODONE [VANDF],oxycontin,Oxycodone 0.1 mg/ml in Methanol,(1S,5R,13R,17S)-17-hydroxy-10-methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10-trien-14-one,Pancodone Retard,Oxicone,4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one,Oxycontin,AC-16043,OXYCODONE CII [USP-RS],(4R,4aS,7aR,12bS)-4a-hydroxy-9-methoxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one,Codeinone, dihydrohydroxy-,CD35PMG570,Oxytrex,Oxycodone cii,Oxyneo,UNII-CD35PMG570,Oxycodonum,BDBM50370595,NSC 19043,Apo-oxycodone CR,HSDB 3142,Ossicodone [DCIT],Morphinan-6-one, 4,5-epoxy-14-hydroxy-3-methoxy-17-methyl-, (5.alpha.)-,Oxycodone solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material,76-42-6,Morphinan-6-one, 4,5-alpha-epoxy-14-hydroxy-3-methoxy-17-methyl-,BRN 0043446,Pancodone retard (United Kingdom),4aH-8,5-bcd]furan-5(6H)-one, 7,7a,8,9-tetrahydro-7a-hydroxy-3-methoxy-12-methyl-,OXYCODONE [MI],OXYCODONE [INN],Codeinone, 7,8-dihydro-14-hydroxy-,oxy,Oxycodone (USAN/INN),oxynorm,4,5alpha-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one,N02AA05,Dihydrohydroxycodeinone,OXYCODONE [HSDB],Dihydrohydroxycondeinone,Eubine [France],OXYCODONE [ORANGE BOOK],WLN: T B6566 B6/CO 4ABBC R BX FV HO PN GHT&&TTJ CQ JO1 P1,(5.ALPHA.)-4,5-EPOXY-14-HYDROXY-3-METHOXY-17-METHYLMORPHINAN-6-ONE,Oxycodone,Q407535,Pavinal,Morphinan-6-one,5-epoxy-14-hydroxy-3-methoxy-17-methyl-, (5.alpha.)-,(4R,4aS,7aR,12bS)-4a-Hydroxy-9-methoxy-3-(2H3)methyl-2,3,4,4a,5,6-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinolin-7(7aH)-one,(5α)-14-Hydroxy-3-methoxy-17-(2H3)methyl-4,5-epoxymorphinan-6-one,14-Hydroxydihydrocodeinone,14-hydroxy-3-methoxy-17-methyl-5beta-4,5-epoxymorphinan-6-one,Morphinan-6-one,5.alpha.-epoxy-14-hydroxy-3-methoxy-17-methyl-,Oxyfast,HYDROCODONE HYDROGEN TARTRATE 2.5-HYDRATE IMPURITY D [EP IMPURITY],Oxycodeinone,Avridi,Xtampza ER,Diphydrone,Oxycodone [USAN:INN:BAN],Tekodin (free base),GTPL7093,Xtampza,Morphinan-6-one, 4,5-epoxy-14-hydroxy-3-methoxy-17-methyl-, (5alpha)-,Supendol,4,5.alpha.-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one,14-hydroxy-3-methoxy-17-methyl-4,5alpha-epoxymorphinan-6-one,Codeinone, dihydro-14-hydroxy-,Oxycodon,D05312,ZINC403533,Oxanest,Percodan,PF06,OXYCODONE [MART.],Remoxy,CHEMBL656


Estimated data

Solubility: -2.636 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: Yes (prediction using frontiersin.org)

Addictivity Prediction: 99.1% (prediction based on www.mdpi.com)

Similarities

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.